0001237899-14-000063.txt : 20140827
0001237899-14-000063.hdr.sgml : 20140827
20140827170226
ACCESSION NUMBER: 0001237899-14-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140826
FILED AS OF DATE: 20140827
DATE AS OF CHANGE: 20140827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessier-Lavigne Marc
CENTRAL INDEX KEY: 0001437435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 141069004
MAIL ADDRESS:
STREET 1: 1 DNA WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2014-08-26
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001437435
Tessier-Lavigne Marc
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2014-08-26
4
M
0
1387.0
50.91
A
1387
D
Common Stock
2014-08-26
4
F
0
200.0
351.62
D
1187
D
Common Stock
2014-08-27
4
M
0
3000.0
50.91
A
4187
D
Common Stock
2014-08-27
4
S
0
3000.0
352.2
D
1187
D
Non-Qualified Stock Option (right to buy)
50.91
2014-08-26
4
M
0
1387.0
0.0
D
2021-11-18
Common Stock
1387
15279
D
Non-Qualified Stock Option (right to buy)
50.91
2014-08-27
4
M
0
3000.0
0.0
D
2021-11-18
Common Stock
3000
12279
D
Represents volume-weighted average price of sales of 3,000 shares of Company stock on August 27, 2014 at prices ranging from $352.15 to $352.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2014 at each separate price.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Marc Tessier-Lavigne
2014-08-27